← All indications
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.
Subtype terms (6)
More specific conditions that are subtypes of Lymphoma in the MeSH hierarchy.
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Composite Lymphoma
8 drugs (7 approved, 1 experimental)
- Hodgkin Disease
455 drugs (202 approved, 253 experimental)
- Immunoproliferative Small Intestinal Disease
- Intraocular Lymphoma
75 drugs (49 approved, 26 experimental)
- Lymphoma, Non-Hodgkin
886 drugs (274 approved, 612 experimental)
Drugs by status
Approved for this indication (16)
Phase 4 trials (56)
- fentanyl
- iron
- granisetron
- cefepime
- etoposide
- teniposide
- Anti-thymocyte Globulin (Rabbit)
- pegloticase
- brentuximab vedotin
- suvorexant
- doxorubicin
- fludarabine
- sargramostim
- ketamine
- aprepitant
- fotemustine
- fluarix
- carboplatin
- Filgrastim
- inactivated influenza vaccine
- palonosetron
- varicella zoster virus glycoprotein e antigen
- plerixafor
- hepatitis b vaccine (recombinant)
- amifostine
- colistin
- epoetin
- ceftazidime
- naltrexone
- cytarabine
- +26 more
Phase 3 trials (156)
- midazolam
- hypericum perforatum
- cd45-depleted allogenic peripheral blood stem cell
- axitinib
- dexrazoxane
- duvelisib
- leucovorin
- procaine benzylpenicillin
- fludeoxyglucose f-18
- elotuzumab
- vinorelbine
- dronabinol
- darbepoetin alfa
- pegaspargase
- dacarbazine
- utomilumab
- cmp-001
- nystatin
- pn-152,243
- dasatinib
- nivolumab
- letermovir
- vorinostat
- piperacillin
- bupropion
- risedronate
- cisplatin
- l-glutamine
- tioguanine
- zoledronic acid
- +126 more
Phase 2 trials (443)
- imatinib
- elimusertib
- ublituximab
- panobinostat
- bcma-pd1-cart cell
- ricolinostat
- meropenem
- ruxolitinib
- mogamulizumab
- tti-622
- dordaviprone
- bvd-523
- daratumumab
- alvocidib
- eribulin
- donor stem cell
- Luminespib
- relma-cel
- chidamide
- surufatinib
- fulvestrant
- navitoclax
- mrna-1273
- valproic acid
- epacadostat
- poly-iclc
- ebv tscm ctl
- human fecal microbiota
- retifanlimab
- pentamidine
- +413 more
Phase 1 trials (396)
- e7766
- anti cd45 monoclonal antibody
- et019003-t cells
- gefitinib
- shr-1501
- trph-222
- tp53-epha-2-car-dc
- allogeneic blood cells
- n-(4-hydroxyphenyl)all-trans retinamide
- biib021
- bms-986178
- alisertib
- lmp 400
- tetradecanoylphorbol acetate
- in111 anti-cd45 monoclonal antibody bc8
- monoclonal antibody e2.3
- acalisib
- irradiated donor lymphocyte
- insulin human
- azd-4877
- gwn323
- cb-010
- autologous lymphocytes
- azd5153
- prt811
- dimethylarsinous glutathione
- e7820
- ly-3039478
- cs1003
- q702
- +366 more
Other trials (44)
- lithium
- rabeprazole
- resca-rd06
- zr-dfo-rb6
- resca-r8b4
- kl-7shrna
- lactobacillus rhamnosus
- foscarnet
- 68ga-dotanoc
- welgenaleucel
- methadone
- allogenic t cell-depleted hematopoietic stem cells
- ga-nota-rd06
- dextrose
- umbilical cord mesenchymal stem cells
- granulocytes
- iodine
- resistant starch
- traumeel
- maltodextrin
- zr-dfo-r8b4
- [18f]rccb6
- il-7/il-15 pre-treated cd19 cells
- jy231
- chia seed
- autologous bone marrow derived mesenchymal cells
- glucose
- nalbuphine
- zr-dfo-rd06
- motexafin lutetium
- +14 more
Organizations
Organization Involved with Phase 4 Indications (70)
- Justus Liebig University Giessen
- University of Texas at Houston
- Wuhan University
- University of Maryland
- Yale University
- Boston University
- Mallinckrodt
- Cornell University
- PETHEMA Foundation
- Seoul National University
- Tsinghua University
- Chinese Academy of Medical Sciences
- Jiao Tong University
- Euronet Worldwide
- Sanofi
- Zhengzhou University
- Swedish Orphan Biovitrum
- Tel Aviv University
- Shanxi Medical University
- Tufts University
- Martin Luther University
- Bristol-Myers Squibb
- Eisai
- Rush University
- Genzyme
- Xinyang Central Hospital
- Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon
- National Cancer Institute (NCI)
- University of Bologna
- J. W. Goethe University
- +40 more
Organization Involved with Phase 3 Indications (296)
- Aarhus University
- Government of China
- National Institute of Allergy and Infectious Diseases (NIAID)
- Chiron
- AbbVie
- Swiss Group for Clinical Cancer Research
- AstraZeneca
- American Scitech International
- Hoosier Cancer Research Network
- Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
- Sichuan University
- Elorac, Inc.
- University of Barcelona
- German Federal Ministry of Education and Research
- Sun Yat-Sen University
- Genentech
- National Center for Research Resources (NCRR)
- McMaster University
- Humanitas University
- Guangxi Medical University
- German Hodgkin's Lymphoma Study Group
- BeOne Medicines
- Newcastle University
- Shire
- Novartis
- Jiangsu Cancer Institute & Hospital
- University of Reims
- GRADE Onlus
- Children's Cancer and Leukaemia Group
- Technical University of Dresden
- +266 more
Organization Involved with Phase 2 Indications (631)
- Medical City Children's Hospital, Dallas
- Keryx
- Soonchunhyang University
- Department of Lymphoma and Hematology, Hunan Cancer Hospital
- University of Santiago
- Array BioPharma
- Siriraj Hospital
- PrECOG, LLC.
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Cyteir Therapeutics, Inc.
- Thermo Fisher Scientific
- University of Toulouse
- Leadiant Biosciences, Inc.
- Brown University
- CHU Hart Leveque
- CerRx, Inc.
- Valerio
- Baylor University
- Azienda Ospedaliera Antonio Cardarelli
- Raffles Hospital, Singapore
- University of Iowa
- Acetylon Pharmaceuticals Incorporated
- University of Florida
- St. Bortolo Hospital
- Indiana University
- Centre Hospitalier ABBEVILLE
- Yiling Pharmaceutical Inc.
- Ospedale Santa Croce-Carle Cuneo
- St. Baldrick's Foundation
- Boryung Pharmaceutical Company
- +601 more
Organization Involved with Phase 1 Indications (210)
- Genzada Pharmaceuticals
- Union Stem Cell & Gene Engineering Co.LTD
- ImmunGene Inc.
- Cho Pharma Inc.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer
- Clinipace LTD
- MingSight Pharmaceuticals Pty Limited
- Veristat, Inc.
- Celator Pharmaceuticals
- California Institute for Biomedical Research
- Saint John Regional Hospital
- Xi'An Yufan Biotechnology Co.,Ltd
- Cascadian Therapeutics Inc.
- Therapeutics, Inc.
- Shattuck Labs
- Oncotartis, Inc.
- MingJu Therapeutics
- Cellular Biomedicine Group Ltd.
- Dong-A Pharmaceutical
- Wuxi No. 4 People's Hospital
- University of California, Berkeley
- Henan Hualong Biotechnology Company
- Ethical Oncology Science
- Cancer Centres of the Carolinas, Greenville, SC 29605
- Shanghai Cell Therapy Group Co.,Ltd
- MedAssessment
- Icon Cancer Centre (Brisbane)
- Nektar Therapeutics
- State of Texas
- Hangzhou HeZheng Pharmaceutical Co., Ltd
- +180 more
Organization Involved with Other Experimental Indications (15)
- Masaryk University
- Cancer Institute WIA
- Shanghai Bioray Laboratory Inc.
- Liaocheng People's Hospital
- Cancer Institute, Adyar, Chennai
- Government of Czech Republic
- Rabin Medical Center
- Upstate Carolina
- Leukosite
- St. Antonius Hospital, Nieuwegein
- Taiwan Cooperative Oncology Group
- PSI Company Ltd.
- Kentuckiana Cancer Institute
- Anhui College of Traditional Chinese Medicine
- Sequenta